Back to News
Market Impact: 0.6
Telix Pharma To Acquire ITM In Deal Worth Up To $2.35 Bln
Source: Nasdaq
M&A & RestructuringHealthcare & BiotechCompany Fundamentals
Telix Pharmaceuticals agreed to acquire privately held ITM Isotope Technologies Munich in a transaction valued at up to US$2.35 billion. The acquisition is intended to strengthen Telix's position in global radiopharmaceuticals and radioisotopes, expanding its strategic capabilities in a key area of nuclear medicine.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.60
Ticker Sentiment
TLX0.72
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- RIP the Cybertruck: Elon Musk says Tesla will wind down production of its most polarizing EV
- Tesla will stop making the Cybertruck in 2027
- Tesla is 'winding down' Cybertruck production at its Texas Gigafactory
- Small retailers brace for 'huge hit' this holiday season as shipping costs spike
- AI won’t pay off for the S&P 493 until CEOs rebuild the work